Table 1.

Baseline characteristics of patients with newly diagnosed AML

CharacteristicIvosidenib 500 mg, N = 34
Age, median (range), y 76.5 (64-87) 
Age category, n (%), y  
 60 to <75 15 (44) 
 ≥75 19 (56) 
Women/men, n 15/19 
ECOG PS at baseline, n (%)  
 0 8 (24) 
 1 20 (59) 
 2 5 (15) 
 3 1 (3) 
Nature of AML, n (%)  
 De novo 8 (24) 
 Secondary  
  History of MDS 18 (53) 
  History of MPD 4 (12) 
  Treatment-related 3 (9) 
  Other 1 (3) 
Prior hypomethylating agent, n (%) 16 (47) 
Cytogenetic risk status by investigator, n (%)  
 Intermediate 24 (71) 
 Poor 9 (26) 
 Unknown 1 (3) 
Bone marrow blasts, median (range), % 63 (1-97) 
Hematology, n (%)  
 White blood cells, ×109/L  
  <15 28 (82) 
  15 to <30 4 (12) 
  ≥30 2 (6) 
 Hemoglobin, g/L  
  <80 5 (15) 
  ≥80 29 (85) 
 Platelets, ×109/L  
  <50 21 (62) 
  ≥50 13 (38) 
Transfusion dependent, n (%)  
 Red blood cells 16 (47) 
 Platelets 14 (41) 
CharacteristicIvosidenib 500 mg, N = 34
Age, median (range), y 76.5 (64-87) 
Age category, n (%), y  
 60 to <75 15 (44) 
 ≥75 19 (56) 
Women/men, n 15/19 
ECOG PS at baseline, n (%)  
 0 8 (24) 
 1 20 (59) 
 2 5 (15) 
 3 1 (3) 
Nature of AML, n (%)  
 De novo 8 (24) 
 Secondary  
  History of MDS 18 (53) 
  History of MPD 4 (12) 
  Treatment-related 3 (9) 
  Other 1 (3) 
Prior hypomethylating agent, n (%) 16 (47) 
Cytogenetic risk status by investigator, n (%)  
 Intermediate 24 (71) 
 Poor 9 (26) 
 Unknown 1 (3) 
Bone marrow blasts, median (range), % 63 (1-97) 
Hematology, n (%)  
 White blood cells, ×109/L  
  <15 28 (82) 
  15 to <30 4 (12) 
  ≥30 2 (6) 
 Hemoglobin, g/L  
  <80 5 (15) 
  ≥80 29 (85) 
 Platelets, ×109/L  
  <50 21 (62) 
  ≥50 13 (38) 
Transfusion dependent, n (%)  
 Red blood cells 16 (47) 
 Platelets 14 (41) 

MDS, myelodysplastic syndrome; MPD, myeloproliferative disease.

Close Modal

or Create an Account

Close Modal
Close Modal